DOW JONES22,327.48+690.70 3.19%
S&P 5002,626.65+85.18 3.35%
NASDAQ7,774.15+271.77 3.62%

Wedbush Maintains Outperform on Stemline Therapeutics, Lowers Price Target to $11

Wedbush analyst David Nierengarten maintains Stemline Therapeutics (NASDAQ:STML) with a Outperform and lowers the price target from $14 to $11.

Benzinga · 03/17/2020 15:32

Wedbush analyst David Nierengarten maintains Stemline Therapeutics (NASDAQ:STML) with a Outperform and lowers the price target from $14 to $11.